Skip to main content

Advertisement

SpringerLink
Log in

Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Several studies have suggested that obesity could have a negative effect on response to anti-tumor necrosis factor α (anti-TNFα) in rheumatoid arthritis (RA). Little is known about the impact of body mass index (BMI) on other biologic agents. We aimed to evaluate the effect of BMI on response to tocilizumab (TCZ) in RA. RA patients treated with TCZ were included in this multicenter retrospective study. BMI was calculated at the initiation of treatment. After 6 months of treatment, change from baseline in DAS28, pain on a visual analog scale, erythrocyte sedimentation rate and C-reactive protein level, and tender and swollen joints were analyzed. The primary endpoint was decrease in DAS28 ≥ 1.2. Secondary outcomes were good response and remission by EULAR criteria. At baseline, among 115 RA patients included, the median (interquartile range) BMI was 25.4 (22.0–28.8) kg/m2. The number of patients with normal weight, overweight, and obesity was 53 (46 %), 37 (32 %), and 25 (22 %), respectively. Baseline characteristics did not differ between the three subgroups of BMI. The median BMI did not differ between responders and non-responders for DAS28 decrease ≥1.2 (25.7 [22.1–29.9] vs 24.9 [22.0–27.1], P = 0.38), EULAR good response (25.9 [22.8–30.0] vs 25.4 [22.0–28.4], P = 0.61), and remission (25.1 [22.5–28.6] vs 25.4 [22.0–28.9], P = 0.76). BMI did not affect the response to TCZ in RA. If confirmed, these results could be helpful for the selection of a biologic agent in obese RA patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. WHO (2000) Obesity: preventing and managing the global epidemic. Tech Rep Ser 894

  2. Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6(10):772–783

    Article  CAS  PubMed  Google Scholar 

  3. Muller-Ladner U, Neumann E (2009) Rheumatoid arthritis: the multifaceted role of adiponectin in inflammatory joint disease. Nat Rev Rheumatol 5(12):659–660

    Article  PubMed  Google Scholar 

  4. Stavropoulos-Kalinoglou A, Metsios G, Koutedakis Y, Kitas G (2011) Obesity in rheumatoid arthritis. Rheumatology (Oxford) 50(3):450–462

    Article  Google Scholar 

  5. Naranjo A, Sokka T, Descalzo M, Calvo-Alén J, Hørslev-Petersen K, Luukkainen R, Combe B, Burmester G, Devlin J, Ferraccioli G et al (2008) Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 10:R30

    Article  PubMed  PubMed Central  Google Scholar 

  6. Armstrong D, McCausland E, Quinn A, Wright G (2006) Obesity and cardiovascular risk factors in rheumatoid arthritis. Rheumatology (Oxford) 45:782

    Article  CAS  Google Scholar 

  7. Voigt L, Koepsell T, Nelson J, Dugowson C, Daling J (1994) Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 5:525–532

    CAS  PubMed  Google Scholar 

  8. Symmons D, Bankhead C, Harrison B, Brennan P, Barrett E, Scott D, Silman A (1997) Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 40:1955–1961

    Article  CAS  PubMed  Google Scholar 

  9. Ajeganova S, Andersson M, Hafström I, Group BS (2013) Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term follow up from disease onset. Arthritis Care Res 65(1):78–87

    Article  Google Scholar 

  10. Westhoff G, Rau R, Zink A (2007) Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 56(11):3575–3582

    Article  CAS  PubMed  Google Scholar 

  11. van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW (2008) A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 67(6):769–774

    Article  PubMed  Google Scholar 

  12. Kaufmann J, Kielstein V, Kilian S, Stein G, Hein G (2003) Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol 30(11):2350–2355

    PubMed  Google Scholar 

  13. Mirpourian M, Salesi M, Abdolahi H, Farajzadegan Z, Karimzadeh H (2014) The association of body mass index with disease activity and clinical response to combination therapy in patients with rheumatoid arthritis. J Res Med Sci 19(6):509–514

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Sandberg ME, Bengtsson C, Kallberg H, Wesley A, Klareskog L, Alfredsson L, Saevarsdottir S (2014) Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis 73(11):2029–2033

    Article  PubMed  Google Scholar 

  15. Klaasen R, Wijbrandts C, Gerlag D, Tak P (2011) Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 63(2):359–364

    Article  CAS  PubMed  Google Scholar 

  16. Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina A et al (2013) Obesity and reduction of the response rate to anti-tumour necrosis factor alphain rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res 65(1):94–100

    Article  CAS  Google Scholar 

  17. Heimans L, van den Broek M, le Cessie S, Siegerink B, Riyazi N, Han KH, Kerstens PJ, Huizinga TW, Lems WF, Allaart CF (2013) Association of high body mass index with decreased treatment response to combination therapy in recent onset rheumatoid arthritis patients. Arthritis Care Res 65:1235–1242

    Article  CAS  Google Scholar 

  18. Minno MD, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, Minno GD (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res 65:141–147

    Article  Google Scholar 

  19. Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman D (2015) Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 74(5):813–817

    Article  PubMed  Google Scholar 

  20. Ottaviani S, Allanore Y, Tubach F, Forien M, Gardette A, Pasquet B et al (2012) Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther 14(3):R115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, Tolusso B, Messuti L, Miceli M, Zoli A et al (2014) Body weight, gender and response to TNF-α blockers in axial spondyloarthritis. Rheumatology (Oxford) 53(5):875–881

    Article  CAS  Google Scholar 

  22. Pers YM, Godfrin-Valnet M, Lambert J, Fortuet C, Constant E, Mura T, Pallot-Prades B, Jorgensen C, Maillefert JF, Marotte H et al (2015) Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient. J Rheumatol 42(4):580–584

    Article  CAS  PubMed  Google Scholar 

  23. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT et al (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581

    Article  PubMed  Google Scholar 

  24. Smolen J, Landewé R, Breedveld F, Dougados M, Emery P, Gaujoux-Viala C et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964–975

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Furst D, Keystone E, So A, Braun J, Breedveld F, Burmester G, De Benedetti F, Dörner T, Emery P, Fleischmann R et al (2013) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 72(Suppl2):ii2–ii34

    CAS  PubMed  Google Scholar 

  26. van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41(10):1845–1850

    Article  PubMed  Google Scholar 

  27. de Rooy D, van der Linden M, Knevel R, Huizinga T, Van der Helm-van Mil A (2011) Predicting arthritis outcomes—what can be learned from the Leiden early arthritis clinic? Rheumatology (Oxford) 50(1):93–100

    Article  Google Scholar 

  28. Neumann E, Frommer K, Vasile M, Muller-Ladner U (2011) Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? Arthritis Rheum 63(5):1159–1169

    Article  CAS  PubMed  Google Scholar 

  29. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71–87

    Article  CAS  PubMed  Google Scholar 

  30. Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25(1):4–7

    Article  CAS  PubMed  Google Scholar 

  31. Zhang J, Fu L, Shi J, Chen X, Li Y, Ma B, Zhang Y (2013) The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies. PLoS One 8(10), e78151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Stavropoulos-Kalinoglou A, Metsios G, Panoulas V, Nightingale P, Koutedakis Y, Kitas G (2012) Anti-tumour necrosis factor alpha therapy improves insulin sensitvity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther 14(4):R160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W (2001) Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86(3):1154–1159

    Article  CAS  PubMed  Google Scholar 

  34. Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, Laudes M (2010) Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 5(12), e14328

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank Laura Smales for copyediting.

Author information

Authors and Affiliations

  1. CHU Bichat Claude Bernard, Service de Rhumatologie, Université Paris Diderot, Hôpital Bichat, AP-HP, 46 rue Henri Huchard, 75018, Paris, France

    A. Gardette, S. Ottaviani, E. Palazzo & P. Dieudé

  2. CHU Saint Antoine, Service de Rhumatologie, DHU i2B and Inserm UMRS_938, Université Pierre et Marie Curie, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France

    J. Sellam & F. Berenbaum

  3. Inserm, UMR-S 606, CHU Lariboisière, Service de Rhumatologie, Université Paris Diderot, 2 rue Ambroise Paré, 75010, Paris, France

    F. Lioté

  4. Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, 1 avenue Molière, 67098, Strasbourg, France

    A. Meyer & J. Sibilia

  5. Service de physiologie exploration fonctionnelle musculaire, Hôpitaux Universitaires de Strasbourg, 1 place de l’Hôpital, 67098, Strasbourg, France

    A. Meyer

  6. CHU La Pitié Salpétrière, Service de Rhumatologie, Université Pierre et Marie Curie, 47-83 boulevard de l’Hôpital, 75013, Paris, France

    B. Fautrel

  7. Inserm, U1149, CNRS-ERL8252, Université Paris Diderot, 46 rue Henri Huchard, 75018, Paris, France

    P. Dieudé

Authors
  1. A. Gardette
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Ottaviani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Sellam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Berenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Lioté
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Sibilia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B. Fautrel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E. Palazzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P. Dieudé
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Dieudé.

Ethics declarations

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gardette, A., Ottaviani, S., Sellam, J. et al. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clin Rheumatol 35, 857–861 (2016). https://doi.org/10.1007/s10067-016-3183-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-016-3183-3

Keywords

Search

Navigation